Skin-derived ABCB5-positive Mesenchymal Stem cells
- Generic Name
- Skin-derived ABCB5-positive Mesenchymal Stem cells
- Drug Type
- Biotech
- Background
Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- RHEACELL GmbH & Co. KG
- Target Recruit Count
- 250
- Registration Number
- NCT06489028
- Locations
- 🇬🇧
RHEACELL Clinical Trial Site, Multiple Locations, United Kingdom
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)
Phase 2
Recruiting
- Conditions
- Skin Ulcer Venous Stasis Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- RHEACELL GmbH & Co. KG
- Target Recruit Count
- 200
- Registration Number
- NCT04971161
- Locations
- 🇩🇪
MVZ Gefäßzentrum Aachen am Marienhospital Aachen GmbH, Aachen, Germany
🇩🇪Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany
🇩🇪Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath